Compare BridgeBio Pharma Inc (BBIO) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard International High Dividend Yield ETF — how do they compare? BridgeBio Pharma Inc trades at $82.54 (market cap $16.46B), while Vanguard International High Dividend Yield ETF trades at $101.15. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | VYMI | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $101.60 |
52-Week Low | $44.81 | $79.76 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
VYMI trades at $100.06, down 0.51% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on international high-dividend stocks, offering diversification and a low 0.07% expense ratio. Recent news highlights its role in hedging against U.S. market concentration and stagflation risks, with strong dividend growth over the past three years.
Outlook remains positive due to attractive international valuations and dividend yield near 4%, though risks include currency fluctuations and global economic slowdowns. Analyst sentiment is favorable, emphasizing long-term growth potential versus U.S. equities, but investors should monitor geopolitical and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
